Brief Report: Predictive value of PD-L1 Expression in non–Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy?

Abstract

• PDL1 expression is a widely used biomarker in selecting patients suitable for immunotherapy. • PDL1 expression over 50% is considered a good predictive biomarker in patients with NSCLC. • New guidelines recommend combination immune and chemotherapy as first line treatment in patients with PDL1 over 1% (including patients with TPS over 50%). • Stratification of patients over 50% of PDL1 expression and response to treatment has not been done. • In our study we showed that very high PDL1 expression (over 80%) is a good predictive biomarker for response to ICI. • Several studies confirmed our results with a relatively small sample size, therefore this could be the guideline for future studies. • Would patients with TPS over 80% benefit more from mono immunotherapy, and patients under that mark from combination immune and chemotherapy? © 2023 Elsevier Inc.